PMID- 10565221
OWN - NLM
STAT- MEDLINE
DCOM- 20000114
LR  - 20071115
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 40
IP  - 10
DP  - 1999 Oct
TI  - [An early phase II study of autologous peripheral blood stem cell transplantation 
      for acute myelogenous leukemia in first remission. Japan Blood Cell 
      Transplantation Study Group].
PG  - 1051-7
AB  - We performed a multicenter, an early phase II clinical trial to evaluate the 
      feasibility, safety and efficacy of myeloablative therapy supported by autologous 
      peripheral blood stem cell transplantation (auto-PBSCT) for the treatment of 
      acute myelogenous leukemia (AML) in first remission. A total of 105 patients were 
      enrolled in the study, and 56 patients in first complete remission received 
      auto-PBSCT. The median age was 44 years. Of the 56 patients, 34 (60.7%) had M2 or 
      M3 AML by the French-American-British Classification system. The median 
      concentration of infused CD34+ cells was 2.3 x 10(6)/kg by recipient body weight. 
      Median days to reach an absolute neutrophil count > 500/microliter and a platelet 
      count > 20000/microliter were 14 and 16, respectively. The median disease-free 
      survival rate was estimated to be 62.0% at a median follow-up time of 534 days. 
      Although the study enrolled a small number of patients and the follow-up period 
      was relatively short, the preliminary results were encouraging and indicated that 
      myeloablative chemotherapy with auto-PBSCT is feasible and can be performed 
      safely as a post-remission therapy for AML. A prospective randomized clinical 
      trial of auto-PBSCT versus standard chemotherapy alone will be necessary to 
      assess the efficacy of high-dose therapy facilitated by auto-PBSCT as a 
      post-remission therapy for AML.
FAU - Kawano, F
AU  - Kawano F
FAU - Kiyokawa, T
AU  - Kiyokawa T
FAU - Shinagawa, K
AU  - Shinagawa K
FAU - Takenaka, K
AU  - Takenaka K
FAU - Imajo, K
AU  - Imajo K
FAU - Hayashi, S
AU  - Hayashi S
FAU - Hirota, Y
AU  - Hirota Y
FAU - Ohno, H
AU  - Ohno H
FAU - Tsuda, H
AU  - Tsuda H
FAU - Gondo, H
AU  - Gondo H
FAU - Shibuya, T
AU  - Shibuya T
FAU - Hisano, S
AU  - Hisano S
FAU - Harada, M
AU  - Harada M
FAU - Ogawa, M
AU  - Ogawa M
FAU - Takaku, F
AU  - Takaku F
LA  - jpn
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Hematopoiesis
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Leukemia, Myeloid, Acute/blood/*therapy
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Transplantation, Autologous
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
PST - ppublish
SO  - Rinsho Ketsueki. 1999 Oct;40(10):1051-7.